Literature DB >> 34896579

Impaired hearing following SARS-CoV-2 vaccinations.

Josef Finsterer1, Fulvio A Scorza2, Ana C Fiorini3.   

Abstract

Entities:  

Keywords:  COVID-19; SARS-CoV-2; adverse reactions; hearing loss; neuro-COVID; vaccination

Mesh:

Substances:

Year:  2021        PMID: 34896579      PMCID: PMC8654803          DOI: 10.1016/j.ijid.2021.12.317

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   12.074


× No keyword cloud information.
Letter to the Editor We appreciated reading the article by Jeong et al. regarding 3 patients developing sensorineural hearing loss (SNHL) 3−16 days after the second Astra Zeneca vaccine (case-1), and after the first (case-2) and second Pfizer vaccine (case-3) (Table 1 ) [Jeong et al. 2021]. Only 2 patients benefited from steroids. In case-3, SNHL deteriorated under treatment [Jeong et al. 2021]. The study is appealing but raises concerns.
Table 1

Reported patients with SNHL following a SARS-CoV-2 vaccination

AgeSexVTLVO (days)SideTROCReference
Individual patients
64f1. AZV3rightprednisoloneCR(Jeong and Choi, 2021)
42m1. BPV0bilprednisoloneIR(Jeong and Choi, 2021)
18m2. BPV16rightprednisoloneDT(Jeong and Choi, 2021)
74f1. MOD7bilnrnr(Wichova et al., 2021)
71m1.+2. MOD2-3rightnrnr(Wichova et al., 2021)
53f1. BPV10bilnrnr(Wichova et al., 2021)
51m1. BPV14rightnrnr(Wichova et al., 2021)
83m2. MOD10leftnrnr(Wichova et al., 2021)
77f2. MID30leftnrnr(Wichova et al., 2021)
69m1. BPV7leftnrnr(Wichova et al., 2021)
67f1.+2. BPVIrightnrnr(Wichova et al., 2021)
60m2. BPV7-14leftnrnr(Wichova et al., 2021)
55m1. BPV10-14rightnrnr(Wichova et al., 2021)
54f2. MOD10-21leftnrnr(Wichova et al., 2021)
49m1. MOD4-5rightnrnr(Wichova et al., 2021)
43m1. MOD14rightnrnr(Wichova et al., 2021)
86m2. BPV42rightnrnr(Wichova et al., 2021)
78f2. BPV1-2roghtnrnr(Wichova et al., 2021)
76m2. MOD14leftmrmr(Wichova et al., 2021)
67m2. MOD7leftnrnr(Wichova et al., 2021)
66f1. BPV7-10leftmrmr(Wichova et al., 2021)
64m2. MOD7-10leftnrnr(Wichova et al., 2021)
61f1. BPV12rightnrnr(Wichova et al., 2021)
59m1. MOD6rgithnrnr(Wichova et al., 2021)
58f1. BPV10bilnrnr(Wichova et al., 2021)
51f1.+2. MOD21rightnrnr(Wichova et al., 2021)
48m1. MOD2-3leftnrnr(Wichova et al., 2021)
39m1. MOD10-14rightnrnr(Wichova et al., 2021)
61f2. AZV2rightsteroids, ASSCR(Tsetsos et al., 2021)
Retrospective cohort studies
N=71nrBPVnrnrnrnr[AIFA 2021]
N=10nrMODnrnrnrnr[AUFA 2021]
N=25nrAZVnrnrnrnr[AIFA 2021]
N=355nrBPVnrnrnrnr(MHRA., 2021)
N=24nrMODnrnrnrnr(MHRA., 2021)
N=724nrAZVnrnrnrnr[(MHRA., 2021)
N=28nrBPV0-21nrnrnr(Formeister et al., 2021)
N=12nrMOD0-21nrnrnr(Formeister et al., 2021)

ASS: acetyl-salicylic acid, AZV: Astra Zeneca vaccine, BPV: Biontech Pfizer vaccine, CR: complete recovery, DT. Deterioration, IR: incomplete recovery, LVO: latency between vaccination and onset of SNHL in days, MOD: Moderna vaccine, nr: not reported, OC: outcome, TR: treatment, VT: type of vaccine,

Reported patients with SNHL following a SARS-CoV-2 vaccination ASS: acetyl-salicylic acid, AZV: Astra Zeneca vaccine, BPV: Biontech Pfizer vaccine, CR: complete recovery, DT. Deterioration, IR: incomplete recovery, LVO: latency between vaccination and onset of SNHL in days, MOD: Moderna vaccine, nr: not reported, OC: outcome, TR: treatment, VT: type of vaccine, We disagree that SNHL is a rare adverse reaction to SARS-CoV-2 vaccines (Jeong and Choi, 2021). Searching the literature revealed that at least 1178 cases with SNHL following a SARS-CoV-2 vaccination have been reported (Table 1). The figure does not include self-reports on the Vaccine Adverse Event Reporting System platform. In the majority of cases, SNHL occurred after the first jab. Most frequently, SNHL occurred in association with the Astra Zeneca vaccine. The authors propose that the viral infection could have been the cause of SNHL, but they do not provide evidence that supports this assumption (Jeong and Choi, 2021). Since it is well appreciated that SARS-CoV-2 vaccinations can cause thrombosis or autoimmune disease, including vasculitis or thrombocytopenia, these other mechanisms should be considered as they are more likely responsible for SNHL than a direct viral attack after SARS-CoV-2 vaccination. It is also conceivable that SNHL is due to mononeuritis of cranial nerve VIII. Mono/polyneuritis of cranial nerves have been repeatedly reported in SARS-CoV-2 infected or vaccinated subjects (Finsterer et al. 2021a) and may or may occur with simultaneous affection of the peripheral nerves (Finsterer et al. 2021b). Additionally, it has been reported that SARS-CoV-2 vaccination can trigger autoimmune disease such as radiculitis. An argument for an immunogenic mechanism of SNHL is that in at least 2 of the index cases a beneficial response to steroids was reported. How can viral infection cause SNHL, as reported in the abstract, when no virus is injected by the vaccination? Unfortunately, the case descriptions of the 3 patients do not provide information if symptoms in addition to SNHL, such as tinnitus, vertigo, dizziness or aural fullness, were noted. Knowing these details and investigating the patients for side effects other than SNHL is crucial for the treatment choice and assessing patient outcomes. Overall, this interesting study has several limitations which challenge the results and their interpretation. SNHL is not infrequent, and the mechanism responsible for SNHL after a SARS-CoV-2 vaccination is rather immunogenic than infectious. Declarations Ethical approval and consent to participate: not applicable Consent for Publication: not applicable Availability of data and material: all data reported are available from the corresponding author Competing interests: none Funding: none received
  4 in total

1.  Preliminary Analysis of Association Between COVID-19 Vaccination and Sudden Hearing Loss Using US Centers for Disease Control and Prevention Vaccine Adverse Events Reporting System Data.

Authors:  Eric J Formeister; Wade Chien; Yuri Agrawal; John P Carey; C Matthew Stewart; Daniel Q Sun
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2021-07-01       Impact factor: 6.223

Review 2.  Guillain-Barre syndrome in 220 patients with COVID-19.

Authors:  Josef Finsterer; Fulvio A Scorza
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2021-05-04

3.  Otologic Manifestations After COVID-19 Vaccination: The House Ear Clinic Experience.

Authors:  Helena Wichova; Mia E Miller; M Jennifer Derebery
Journal:  Otol Neurotol       Date:  2021-07-09       Impact factor: 2.311

  4 in total
  1 in total

1.  Acute Unilateral Peripheral Vestibulopathy After COVID-19 Vaccination: Initial Experience in a Tertiary Neurotology Center.

Authors:  Marc Basil Schmid; David Bächinger; Athina Pangalu; Dominik Straumann; Julia Dlugaiczyk
Journal:  Front Neurol       Date:  2022-07-01       Impact factor: 4.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.